Trial Profile
Lenalidomide Maintenance Therapy in Multiple Myeloma: A Phase II Clinical and Biomarker Study
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Biomarker; Therapeutic Use
- 08 Jan 2018 Status changed from completed to discontinued.
- 11 Mar 2017 Status changed from active, no longer recruiting to completed.
- 19 Apr 2015 Planned End Date changed from 1 Aug 2016 to 1 April 2018 as reported by ClinicalTrials.gov record.